Arthritis Advisory Committee

On July 13, 2016, the Arthritis Advisory Committee (AAC) supported by a vote of 20-Yes to 0-No, with no  abstentions, that the totality of the evidence supports licensure of GP2015, a proposed biosimilar to Amgen Inc.’s Enbrel (etanercept), submitted by Sandoz, Inc. (Sandoz), a unit of Novartis AG.